Tempus AI to Acquire Personalis for 1.5 Billion USD

CHICAGO, USA - Tempus AI, Inc. (NASDAQ: TEM), a leader in AI-enabled precision medicine, has announced a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The transaction, valued at 1.5 billion USD net of Tempus' existing ownership, aims to integrate Personalis' molecular residual disease (MRD) technology into Tempus' existing AI-driven oncology platform.

The acquisition builds upon an existing partnership between the two companies established in November 2023. By combining Tempus' multimodal data and AI capabilities with the NeXT Personal MRD test, the companies plan to enhance cancer monitoring, biomarker discovery, and personalized patient care across the cancer care continuum.

Transaction Details

• Consideration: 16.25 USD per share of common stock.
• Total Enterprise Value: 1.5 billion USD.
• Structure: 100% stock transaction, with Tempus retaining the option to pay up to 50% in cash.
• Approval: Approved by the boards of directors of both companies; subject to shareholder and regulatory approvals.
• Expected Closing: Late 2026 or early 2027.

The acquisition positions Tempus to expand its influence in the rapidly growing MRD market, which is estimated to represent a 20 billion USD opportunity. Personalis recently reported preliminary Q2 revenue of 22.4 million USD and a 33% increase in quarterly test volumes, underscoring the growing demand for longitudinal cancer monitoring technology.